NHF and HFA Letter to Genentech Announcement of Particulate Matter in Emicizumab (HEMLIBRA)

October 10, 2019

The National Hemophilia Foundation and the Hemophilia Federation of America continue to follow up on issues arising from Genentech’s recent announcement regarding reports of particulate matter in vials of Hemlibra. You can read comments on the statement from NHF’s Medical and Scientific Advisory Council (MASAC). Today HFA and NHF sent Genentech a letter with additional questions, which you can read here.

We recognize that the joint HFA-NHF letter does not answer all the questions you may have arising from this situation. HFA and NHF remind you to please reach out to your physician with any medical concerns.

We also remind you that Genentech has provided their call center number if you want to ask them questions. That number is 1-800-821-8590. You may also report adverse medical events directly to the U.S. Food and Drug Administration (1-800-FDA-1088).

HFA and NHF are in continuing contact with Genentech regarding this matter. As always, HFA and NHF will keep the bleeding disorders community informed as we learn more.

Please note that HFA and NHF do not recommend, endorse or make any representation about the efficacy, appropriateness or suitability of any specific products, treatments or opinions. If you have any questions or concerns about your medical treatment, including your possible exposure to recalled product, please consult your physician. Events like this one can cause a myriad of emotions. Please reach out to a social worker, provider, or trusted source of support.